



ABOUT US:


NurExone Biologic Inc. is a publicly-traded biopharma company, listed on the Toronto Stock Exchange (TSXV: NRX), the OTCQB Venture Market (OTCQB:NRXBF) and Frankfurt Stock Exchange (TSXV: NRX). NurExone is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs.

EXOSOMES AS A DELIVERY MECHANISM

ExoTherapy Platform

- ▶ Exosomes are small particles created when stem cells proliferate and they can possess “homing” capability, targeting specific tissues and inflammation in the body
- ▶ We use exosomes as “guided missiles”, targeting specific tissues
- ▶ Our exosomes can be loaded with a wide range of molecules, such as siRNA to enhance their inherent therapeutic potential






Program	Indication	Discovery	Preclinical Development	Regulatory Strategy	Studies for IND (toxicity, efficacy)	Phase I
ExoPTEN	Acute Spinal Cord Injury	[Progress bar]				
	Glaucoma	[Progress bar]				
PNN Targeting Sequences	Several - CNS Traumatic Injury	[Progress bar]				
Exosomes and Stem Cells	Chronic Spinal Cord Injury	[Progress bar]		Collaboration with Inteligex leverages their novel targeted human stem cell platform which replaces key cell types lost due to traumatic injury or neurodegeneration		

POTENTIAL FOR LICENSING OR COLLABORATION AGREEMENTS WITH BIG PHARMA



- ✓ Approved or under-development drugs that cannot currently be delivered to the brain because they can't cross the blood-brain-barrier
- ✓ Repurpose of products in low dosing or safer manner (nanoparticles that can penetrate cells)
- ✓ Biological or stem cell delivery to achieve a synergistic effect

NUREXONE'S LEAD ASSET IS EXOPTEN

Born in the labs of Israel's Technion, ExoPTEN is NurExone's first nanodrug. Being developed for patients who have suffered acute spinal cord injury. ExoPTEN uses exosomes loaded with a specific and proprietary siRNA sequence as the active pharmaceutical ingredient.

-  **ExoPTEN is the first known minimally invasive therapy** that has successfully promoted nerve regeneration and functional recovery following complete spinal cord transection
-  **Recovery of motor function, sensation, and bladder control was observed in 75% of animals** after a brief intranasal ExoPTEN treatment cycle
-  Showed **functional restoration of damaged eyes to healthy levels** in animals (Glaucoma)



					
EXOTHERAPY PLATFORM PROVIDES SEVERAL BENEFITS					
Comparison	ExoPTEN Technology	Autologous Stem Cell	Allologous Stem Cell	Epidural Electrical Stimulation	Monoclonal antibody, growth factors
Potential to repair full transection	✓	✓	✓	✗	✗
Non immunogenic	✓	✓	✗	✓	✓
Off the shelf use	✓	✗	✓	✓	✓
Minimally invasive	✓	✗	✗	✗	✗

LED BY AN EXPERIENCED MANAGEMENT TEAM



Dr. Lior Shaltiel
CEO & Director



Mr. Eran Ovadya
Chief Financial Officer



Dr. Ina Sarel
Head of CMC,
Quality and Reg.



Dr. Tali Kizhner
R&D Director



Mr. Yoram Drucker
Co-Founder, VP Strategic
Development & Chairman



info@nurexone.com
nurexone.com

NurExone
Website



In Vivo
POC



Animation
Video



Corporate
Overview

